progression-free survival

Advancing Treatment in ER-Positive, HER2-Negative Advanced Breast Cancer: Efficacy of Giredestrant Plus Everolimus

By MedXY 10/27/2026

A phase 3 trial demonstrates that the oral combination of giredestrant and everolimus significantly improves progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer post-CDK4/6 inhibitor therapy, especially in ESR1-mutated tumors, with a manageable safety profile.

Hematology-Oncology news Oncology

Long-Term Efficacy and Safety of First-Line Ibrutinib-Venetoclax in Older Patients with Chronic Lymphocytic Leukemia: Insights from the 67-Month GLOW Study

By MedXY 10/08/2026

The GLOW phase III trial demonstrates that fixed-duration ibrutinib-venetoclax provides superior overall survival, progression-free survival, and safety compared to chlorambucil-obinutuzumab in older/comorbid CLL patients, with durable disease control and reduced need for second-line therapy.

news OB/GYN & Women’s Health Oncology

Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up

By MedXY 09/21/2026

A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients with KRAS mutations.

Hematology-Oncology Internal Medicine news

Optimizing Outcomes in POEMS Syndrome: Real-World Insights on Autologous Stem Cell Transplantation from a Multicenter Study

By MedXY 08/05/2026

This multicenter study evaluates autologous stem cell transplantation (ASCT) in POEMS syndrome, showing significant hematologic response, durable survival, and manageable toxicity, highlighting ASCT's pivotal role in treatment.

news OB/GYN & Women’s Health Oncology

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY 06/10/2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.

news OB/GYN & Women’s Health Oncology

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY 06/03/2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source

By MedXY 05/04/2026

A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.

Hematology-Oncology news Oncology

Five-Year POLARIX Follow-Up: Polatuzumab-R-CHP Improves Long-Term PFS in Frontline DLBCL — What Clinicians Need to Know

By MedXY 12/11/2025

At five years, pola‑R‑CHP showed a sustained progression‑free survival benefit versus R‑CHOP in newly diagnosed intermediate‑/high‑risk DLBCL (HR 0.77), with similar long‑term tolerability and no statistically significant overall survival difference.

Gastroenterology news Oncology

Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival

By MedXY 11/05/2025

Olverembatinib showed outstanding efficacy in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), significantly extending median progression-free survival to 25.7 months compared to traditional therapies.

Gastroenterology news Oncology

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival

By MedXY 10/28/2025

This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need for better surrogate markers in clinical trials.

news Oncology Otorhinolaryngology

Imaging-Detected Extranodal Extension as a Predictor of Distant Recurrence in HPV-Positive Oropharyngeal Cancer

By MedXY 10/22/2025

Imaging-based extranodal extension (iENE) in HPV-positive oropharyngeal cancer predicts higher rates of distant metastases and decreased progression-free survival, highlighting its prognostic significance and potential role in refining staging and treatment planning.

Hematology-Oncology news Oncology

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy

By MedXY 10/14/2025

Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal residual disease outcomes.

Hematology-Oncology news Oncology

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

By MedXY 10/14/2025

The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in advanced ISS stages and select genetic subgroups.

Hematology-Oncology news Oncology

Ibrutinib-Rituximab versus Immunochemotherapy: A Paradigm Shift in First-Line Treatment for Older Mantle Cell Lymphoma Patients

By MedXY 10/10/2025

The ENRICH trial demonstrates that ibrutinib combined with rituximab significantly improves progression-free survival compared to standard immunochemotherapy in older patients with untreated mantle cell lymphoma, heralding a new chemotherapy-free standard of care.

Clinical Updates Oncology Specialties

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

By MedXY 09/08/2025

The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting safety concerns that preclude further development.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Everolimus Plus Carboplatin: A Promising Combination for Advanced Triple-Negative Breast Cancer

By MedXY 09/01/2025

A phase 2 study shows adding everolimus to carboplatin significantly improves progression-free survival in advanced TNBC with manageable safety profile, indicating a potential new treatment avenue.

Clinical Updates Hematology-Oncology news Specialties

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma

By MedXY 08/30/2025

This phase 2 study demonstrates that obinutuzumab plus lenalidomide achieves high response rates with durable progression-free survival and manageable toxicities in untreated high tumor burden follicular lymphoma, suggesting a promising frontline option.

news Oncology Specialties

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial

By MedXY 08/13/2025

The EREMISS trial demonstrates that regorafenib significantly prolongs progression-free survival as maintenance therapy after first-line doxorubicin chemotherapy in advanced non-adipocytic soft tissue sarcoma patients, with manageable safety profiles.

Clinical Updates Hematology-Oncology news Specialties

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

By MedXY 08/07/2025

Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.

Clinical Updates Hematology-Oncology news Specialties

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY 08/07/2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxicity.